Investor Presentaiton

Core US Market S Momentum and opportunity remain significant With coverage for basal insulin users and problematic hypoglycemia there is more people with access to CGM than ever before Dexcom Insulin & Non-Insulin Hypoglycemia Population 2016 2017 2018 2019 2020 2021 2022 CMS Basal CMS Hypo Commercial Coverage Coverage Basal (60%+) Estimated US IIT CGM Users - All companies* Estimated Reimbursed Population* T1 Commercial + Medicare (T1 + T2 IIT) + Medicaid + T2 IIT Commercial *Dexcom market research and Wall Street research. Estimated Reimbursed Population based on Dexcom market research. Basal-Only & Problematic Hypo All Insulin ~7m IIT ~4m 15

View entire presentation